Risk-based monitoring (RBM) can deploy monitoring resources deeply and selectively where and when they are most needed. Given the expensive and long-timeline nature of most oncology development programs, the data-quality improvement from RBM could reduce risks by driving signal identification, and confirmation of its absence if applicable, faster.
In this white paper, our experts examine the benefits of transitioning ongoing oncology studies to a RBM approach, and what must be done to make that transition happen.
Download the white paper below
